Canadian government supports SFU VentureLabs Alumni, Aspect Biosystems with $79 Million in funding. On April 2nd, the Government of Canada announced an investment of $79 Million for SFU VentureLabs Alumni, Aspect Biosystems. This initiative was conducted through the Strategic Response Fund (SRF), a fund focused on supporting Canadian industries' innovation, adaptation and competition in an evolving global economy. The Province of British Columbia will also be supporting Aspect Biosystems with $23.8 million to expand the company. The national government is strengthening its partnership with Aspect Biosystems with an additional $280 million collaboration that supports the scaling of Aspect's clinical development, enhances their AI-platform and accelerates the commercialization process. This installation will create upwards of 400 jobs for employees and co-op students alike. Aspect Biosystems' CEO, Tamer Mohammed remains enthusiastic about this joint effort. "With this investment and the deepening of our partnership with the Government of Canada, we are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world.", said Mohammed Tamer, CEO of Aspect Biosystems

InBC has invested in Vancouver-based Aspect Biosystems, a biotech firm developing bioprinted tissue therapeutics for diseases like diabetes and obesity. The company partners with Novo Nordisk to create treatments for type 1 diabetes. This investment supports Aspect's expansion and aligns with B.C.'s strategy to become a life sciences hub. Aspect previously received funding from Canadian and B.C. governments to enhance its biomanufacturing capabilities.